Incyte Corp (INCY) Stock AnalysisINCYIncyte Corp

Incyte Corporation is a biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutics. It operates in three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity. Its hematology franchise includes four approved products, JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) and NIKTIMVO (axatilimab-csfr), as well as multiple clinical development programs. Its oncology franchise includes two approved products, PEMAZYRE (pemigatinib) and ZYNYZ (retifanlimab-dlwr), as well as several clinical development programs. Its Inflammation and Autoimmunity franchise consists of one approved product, OPZELURA (ruxolitinib) cream, with several clinical programs in development. It also includes VGA039, a novel monoclonal antibody in Phase III development for von Willebrand disease (VWD). It manages business activities through the development and commercialization of oncology and dermatology products. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

Incyte Corp is a good buy right now due to its current price of $115.71 being below the analyst price target of $157 from Stifel, indicating significant upside potential. Additionally, the stock has shown a strong year-to-date change of +14.09% and a one-year change of +24.31%, reflecting solid performance. The RSI is at 55.026, suggesting the stock is neither overbought nor oversold, which is favorable for entry. However, a risk to consider is the upcoming earnings report on October 29, where the EPS estimate is -3.94, which could impact sentiment if results disappoint.

21 analysts cover INCY: 17 rate it Buy, 4 Hold and 0 Sell. The average price target is 100.31.